Mirapex ER 0,375 mg 30 tablets — Made in Germany — Free Delivery

Mirapex ER tablets are indicated in adults for the treatment of symptoms of idiopathic Parkinson's disease, either alone (without levodopa) or in combination with levodopa, that is, throughout the course of the disease. For the treatment of advanced stages, when the effect of levodopa is weakened or becomes unstable, as well as fluctuations in the therapeutic effect are observed (discontinuation of the dose or fluctuations according to the principle "active - inactive").

Active ingredient: pramipexole;

1 extended-release tablet contains:

Excipients: hypromellose 2208, corn starch, carbomer 941, colloidal silicon dioxide, magnesium stearate.

Hypersensitivity to pramipexole or to any other component of the preparation.

Mirapex ER extended-release tablets are a once-daily dosage form of pramipexole.

Doses should be increased gradually, starting with a dose of 0.375 mg pramipexole dihydrochloride monohydrate per day, with subsequent increases every 5-7 days. If there are no intolerable side effects in patients, then dose titration should be carried out to achieve the maximum therapeutic effect.

The preparation can be used during pregnancy only if the expected benefit to the woman outweighs the potential risk to the fetus.

The safety and efficacy of the preparation in children (under the age of 18) have not been established. There is no justification for the use of the preparation in children with Parkinson's disease.

Pramipexole may have a significant effect on the ability to drive or use machines. You may experience hallucinations or drowsiness.

Patients with drowsiness and / or episodes of sudden onset of drowsiness while using pramipexole should refrain from driving vehicles and from potentially hazardous activities where impaired attention increases the risk of serious injury or death.

There is no clinical experience of significant overdose. Expected adverse reactions may be those related to the pharmacodynamic profile of the dopamine agonist, including nausea, vomiting, hyperkinesia, hallucinations, anxiety, and hypotension. There is no established antidote for dopamine agonist overdose. If there are signs of stimulation of the central nervous system, an antipsychotic may be indicated. Treatment of overdose may require general supportive measures along with gastric lavage, fluid administration, activated charcoal, and electrocardiogram monitoring.

In patients with Parkinson's disease treated with pramipexole, the most common adverse reactions were nausea, dyskinesia, arterial hypotension, dizziness, drowsiness, insomnia, constipation, hallucinations, headache and fatigue.

The simultaneous use of antipsychotic preparations (neuroleptics) with pramipexole should be avoided if antagonistic effects are expected.

Cimetidine reduces the renal clearance of pramipexole by approximately 34%, probably by suppressing the renal tubular cation transport system.

Store in the original packaging in a dry place to protect from moisture, at a temperature not exceeding 25°C.

Keep out of the reach of children!

Shelf life - 3 years.